MARKET

CNCE

CNCE

Concert Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.92
+0.07
+1.04%
Opening 13:24 02/24 EST
OPEN
7.01
PREV CLOSE
6.85
HIGH
7.13
LOW
6.82
VOLUME
144.38K
TURNOVER
--
52 WEEK HIGH
13.50
52 WEEK LOW
5.47
MARKET CAP
212.14M
P/E (TTM)
-2.6882
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Concert Pharmace Down 33.9% Since SmarTrend Downtrend Call (CNCE)
SmarTrend identified a Downtrend for Concert Pharmace (NASDAQ:CNCE) on January 21st, 2021 at $10.81. In approximately 1 month, Concert Pharmace has returned 33.86% as of today's recent price of $7.15.
Comtex SmarTrend(R) · 1d ago
Tyrosine Protein Kinase JAK1 Market Size, Share, Global Growth 2021, by Manufacturers, Regions, Application and Forecast to 2026
The Express Wire · 1d ago
BioMedNewsBreaks - Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Featured in Research Report
Feb 22, 2021 (Investor Brand Network via COMTEX) -- Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products...
Investor Brand Network · 2d ago
Gastric Motility Disorder Drug Market Global Industry Share, Size, Global Industry Analysis, Key Growth Drivers Trends, Segments, Emerging Technologies, Opportunity and Forecast 2020 to 2027 By Ameco Research
pune, India, Mon, 22 Feb 2021 01:43:42 / Comserve Inc. / -- Gastric Motility Disorder Drug market is segmented by Type, and by Application. Players,...
Comserve · 2d ago
The Week Ahead In Biotech: J&J Vaccine Adcom Meeting, Sarepta FDA Decision And Plenty Of Earnings
Biotech stocks pulled back along with the broader market in the holiday-shortened week ended Feb 19. Earnings news flow was light before picking up pace in the unfolding week.
Benzinga · 4d ago
Press Release: Concert Pharmaceuticals to Report Full Year 2020 Results on February 25, 2021
Dow Jones · 6d ago
Alopecia Market SWOT Analysis, Top Players - Johnson & Johnson Services Inc., Cirrus Hair Centers, Cipla Inc., Follica Inc, Etc
Feb 17, 2021 (Market Insight Reports) -- Rising occurrences of alopecia and increasing incidence of chronic diseases are among the significant factors...
Market Insight Reports · 02/17 15:48
Global Tyrosine Protein Kinase JAK1 Market Size 2021 Top Manufacturers Strategy By Industry Sales, Progression Status, Emerging Demands, On Going Trends, Business Opportunity, Share and Forecast To 2027 Says, Industry Research Biz
The Express Wire · 02/15 05:15
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CNCE. Analyze the recent business situations of Concert Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CNCE stock price target is 15.00 with a high estimate of 22.00 and a low estimate of 11.00.
EPS
Institutional Holdings
Institutions: 154
Institutional Holdings: 26.92M
% Owned: 87.85%
Shares Outstanding: 30.65M
TypeInstitutionsShares
Increased
34
1.46M
New
25
1.57M
Decreased
31
635.24K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.29%
Pharmaceuticals & Medical Research
+1.33%
Key Executives
Chairman/Co-Founder/Independent Director
Richard Aldrich
President/Chief Executive Officer/Co-Founder/Director
Roger Tung
Chief Financial Officer/Chief Accounting Officer
Marc Becker
Chief Operating Officer
Nancy Stuart
Other
James Cassella
Other
James Cassella,
Secretary
Jeffrey Munsie
Independent Director
Thomas Auchincloss
Independent Director
Ronald Barrett
Independent Director
Jesper Hoiland
Independent Director
Peter Hutt
Independent Director
Wilfred Jaeger
Independent Director
Christine van Heek
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
About CNCE
Concert Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company's deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas. Its product candidates include AVP-786, CTP-656, CTP-730, CTP-543 and JZP-386. The Company's product candidate, CTP-656, is a next generation potentiator that it is initially developing for the treatment of cystic fibrosis in patients having gating mutations, including the G551D mutation. CTP-543 was discovered by applying Concert's deuterium chemistry technology to modify ruxolitinib. AVP-786 is a combination of a dextromethorphan and an ultra-low dose of quinidine. CTP-730 is a phosphodiesterase 4 (PDE4) inhibitor that has potential for the treatment of various inflammatory diseases.

Webull offers kinds of Concert Pharmaceuticals Inc stock information, including NASDAQ:CNCE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CNCE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CNCE stock methods without spending real money on the virtual paper trading platform.